Penserra Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Penserra Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-820	Closed	-$13K	–	1504
2021 Q3	$13K	Buy	820 +5	+0.6%	+$106	﹤0.01%	1316
2021 Q2	$23K	Buy	815 +15	+2%	+$467	﹤0.01%	1125
2021 Q1	$31K	Sell	800 -25	-3%	-$812	﹤0.01%	899
2020 Q4	$18K	Buy	+825	New	+$20.7K	﹤0.01%	860

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Penserra Capital Management's PLRX Position: Q4 2021 in Review

Penserra Capital Management sold out of Pliant Therapeutics (PLRX) in Q4 2021, closing a stake of 820 shares — an estimated $13K sold.

Penserra Capital Management first reported a position in PLRX in Q4 2020 and held it in 4 quarters. The position peaked at $31K in Q1 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q4 2021.

Penserra Capital Management reported no remaining Pliant Therapeutics position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 820 Pliant Therapeutics shares in Q4 2021, an estimated $13K.
Penserra Capital Management first reported a position in Pliant Therapeutics in Q4 2020 and held it in 4 quarters.
Penserra Capital Management's Pliant Therapeutics position peaked at $31K in Q1 2021.
88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.